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Abstract 
Abnormal patterns of DNA methylation are one of the hallmarks of cancer cells.  The process of 
aging has also been associated with similar, albeit less dramatic, changes in methylation patterns, 
leading to the hypothesis that age-related changes in DNA methylation may partially underlie the 
increased frequencies of cancer in the elderly. Here we studied 377 participants aged 85 years from 
the Newcastle 85+ Study, to investigate the extent of, and inter-individual variation in, age-related 
changes in DNA methylation at specific CpG islands. Using highly quantitative pyrosequencing 
analysis, we found extensive and highly variable methylation of promoter associated CpG islands 
with levels ranging from 4-35%, even at known tumor suppressor genes such as TWIST2. 
Furthermore, the inter-individual differences in methylation seen across this elderly population 
phenocopies multiple features of the altered methylation seen in cancer cells. Both aging and 
cancer–related methylation can occur at similar sets of genes, both result in the formation of densely 
methylated, and likely transcriptionally repressed, alleles and both exhibit co-ordinate methylation 
across multiple loci. In addition, high methylation levels were associated with subsequent diagnosis 
of leukemia or lymphoma during a 3 year follow-up period (p=0.00008). These data suggest that the 
accumulation of age-related changes in promoter methylation may contribute to the increased 
cancer risk seen during aging. 
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Introduction 
 Cancer is one of the leading causes of death world-wide. The risk of almost all types of 
cancer increases with age and population aging is expected to be one of the primary drivers of the 
predicted dramatic increases in cancer incidence in the next 20 years (1). Thus, despite the 
improved success of treatment of most types of cancer, it is likely that the burden of cancer in the 
world’s population will continue to increase. 
 DNA methylation, which occurs almost exclusively at CpG dinucleotides, is an important 
epigenetic mechanism for controlling gene expression (2). In particular, hypermethylation of gene 
promoters which have high densities of CpG sites, known as CpG islands, is associated with 
chromatin compaction and consequent loss of gene expression (3). This is a critical mechanism for 
control of expression of imprinted genes, for X-chromosome inactivation and for many germ cell 
specific genes (2). However, although the majority of human genes possess a promoter associated 
CpG island, these generally remain methylation free, even in tissues where the associated gene is 
not expressed (3). The development of cancer is associated with dramatic shifts in the pattern of 
DNA methylation (4). These include global reduction in genome wide levels of DNA methylation, 
highly variable methylation at CpG island shores and increased methylation of promoter-associated 
CpG islands. This increased CpG island methylation is often associated with gene silencing and the 
altered DNA methylation has been shown to be required for maintaining transcriptional inactivation 
of the linked gene (5). Many genes known to be important in cancer development, including the 
tumor suppressor genes MLH1 and BRCA1 (6) are inactivated by this mechanism. 
However, these methylation changes are not unique to cancer and similar, albeit less 
dramatic, changes are also seen in apparently healthy individuals during aging (7). Cross-sectional 
studies have reported that global levels of DNA methylation reduce with age (8), although cohort 
studies, in which methylation was measured in the same individual several years apart, have shown 
that the accumulation of age-related methylation changes can be highly individual (9). Furthermore,  
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promoter associated CpG islands  can exhibit increasing levels of DNA methylation with increasing 
age (7).  
Based on these observations we hypothesized that the gradual acquisition of abnormalities in 
the pattern of DNA methylation during aging increases cancer risk and thus partially underlies the 
strong link between older age and greater risk of most types of cancer (10). In addition, it has been 
speculated that the altered methylation will likely result in age-related changes in gene expression 
which may have subsequent impacts on the development of other age-related illnesses (11). Several  
age-related illnesses are associated with changes in DNA methylation at specific genes, suggesting 
a potentially significant role for altered DNA methylation in the development of these disorders 
(11). 
If the acquisition of age-related methylation changes varies widely between individuals, this 
could play a key role in differential susceptibility to the development of cancer and other diseases 
associated with aging. However, the extent of, and inter-individual variability in, CpG island 
methylation in apparently healthy people across the life-course is not well understood. To begin to 
assess whether differences in the acquisition of altered methylation patterns during aging impacts 
on health, we have examined CpG island methylation in peripheral blood DNA from a large cohort 
of 85 year olds from the Newcastle 85+ Study. This strategy has the advantage that, as all 
participants are the same age, all variation detected represents inter-individual variation with no 
confounding due to differences in chronological age. Furthermore, by studying a population of the 
oldest old, any inter-individual differences in age- associated methylation changes are likely to be 
maximized.  
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Materials and Methods 
Study population 
DNA was extracted from peripheral blood leukocytes from 377 participants from the 
Newcastle 85+ study. The analysis was initially performed as a pilot study on 50 samples 
(consisting of 25 survivors (at 3 years follow-up) and 25 non-survivors). After successful analysis 
of the pilot study samples the analysis was extended to all participants with a previous cancer 
history (n=113), all participants with an incident cancer diagnosis (at 3 years follow-up, n=72, 20 of 
whom were also in the previous cancer history group) and a control group without a history of 
cancer or an incident diagnosis (n=212). The methodology for the Newcastle 85+ Study has been 
reported (12, 13). In brief, members of the 1921 birth cohort living in Newcastle or North Tyneside 
(North-East England) were recruited at approximately age 85 through general practice patient lists. 
People living in institutions and those with cognitive impairment were included.  The research 
complied with the requirements of the Declaration of Helsinki. Ethical approval was obtained from 
the Newcastle and North Tyneside 1 Research Ethics Committee (reference number 06/Q0905/2). 
Written informed consent was obtained from participants and where people lacked capacity to 
consent, for example because of dementia, a formal written opinion was sought from a relative or 
carer. Information on previous cancer history and incident cancer diagnoses (at 3 years) was 
obtained from the general practice medical records. In the UK, patients are registered with a single 
general practice which acts as a gatekeeper to secondary care and receives details of all hospital 
admissions and outpatient attendances. The review of general practice records included hospital 
correspondence to ensure that all recorded disease diagnoses were extracted irrespective of where 
and when the diagnosis was made.  
 To allow analysis of methylation at different ages another 150 DNA samples were obtained. 
These consisted of 50 DNA samples extracted from cord blood from newborns and 50 extracted 
from peripheral blood of their mothers (median age 28 years old) from the North Cumbria 
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Community Genetics Project  (14) and 50 peripheral blood DNA samples from the 50 year old 
participants from the Newcastle Thousand Families Study (15). 
 
DNA modification and PCR 
200ng of genomic DNA was modified with sodium bisulfite using the MethylampTM One-
Step DNA Modification Kit (Epigentek, Brooklyn, NY, USA) as per the manufacturer’s 
instructions. All samples were re-suspended in 15μl of TE and 1μl of this was used for subsequent 
PCR reactions. The samples were amplified in 25μl volumes containing 1X manufacturer’s buffer, 
1 unit of FastStart Taq polymerase (Roche, Welwyn Garden City, UK), 1-4mM MgCl2, 10mM 
dNTPs, and 75ng of each primer. PCR was performed with one cycle of 95oC for 6min, 40 cycles 
of 95oC for 30sec, 57-63oC for 30sec and 72oC for 30sec, followed by one cycle of 72oC for 5min. 
For each set of primers (listed in Table 1) one of the forward or reverse primers included a 5’ biotin 
label to allow for subsequent analysis by pyrosequencing.  
 
Quantitative DNA methylation analysis using pyrosequencing 
 Following PCR amplification sequencing was performed using a PSQ 96MA pyrosequencer 
(Qiagen, Hilden, Germany), as per manufacturer’s protocol. For all loci, assays were performed in 
duplicate and values averaged between the duplicates. Only samples that were passed by the 
pyrosequencer were included and to further ensure a high degree of accuracy only runs in which 
single peak heights were in excess of 200 were included. Samples in which the repeats varied in 
excess of 2% methylation were repeated one additional time and the average taken across the three 
repeats.  
 For each locus between 3 and 6 consecutive CpG sites were measured and the methylation 
value for each loci was taken as the mean of all CpG sites measured at that loci. Methylation values 
at consecutive CpG sites were strongly correlated, with correlation coefficients between consecutive 
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CpG sites ranging from 0.93-0.98 (TWIST2), 0.87-0.93 (TUSC3), 0.63-0.87 (HAND2), 0.80-0.86 
(HOXD4), 0.42-0.64 (EPHA10) and 0.96-0.98 (HOXA5). 
 Primer design was performed using the manufacturer’s provided PyroMark software. For 
initial assessment of all assays pyrosequencing was carried out on samples of known methylation 
status (5,10, 15, 20, 50, 70 and 100% methylated), which were produced by diluting peripheral 
blood derived DNA (from a young adult volunteer) into in vitro methylated DNA (Millipore, 
Watford, UK). . Only assays which produced correlations with R2 of ≥0.90 were used for further 
analysis. 
 
Derivation of overall methylation level 
 To produce a more accurate estimate of the comparative levels of age-related CpG island 
methylation in the samples, the values for each of the 5 age-related loci examined in the full sample 
set (EPHA10, HOXD4, HAND2, TUSC3, TWIST2) were averaged. The values at the 5 loci were 
weighted prior to averaging to ensure an equal contribution from each locus to the final average. 
The percentage of lymphocytes in each peripheral blood sample was highly variable (8-
56%) and was found to correlate strongly with overall methylation levels. To correct for this effect 
a correlation analysis was performed between overall methylation and lymphocyte percentage. The 
slope of the regression line produced was calculated to determine the average increase in 
methylation per 1% increase in lymphocyte percentage (slope =0.1811). This was then used to 
correct all values back to the average percentage of lymphocytes in the population (29.0%). 
 
Bisulfite sequencing 
Sodium bisulphite modification and PCR was carried out as above. PCR products were then cloned 
using the TA Cloning® Kit (Invitrogen Ltd, Paisley, UK), as per manufacturer’s protocol. 2μl of the 
ligation product was transformed into One Shot TOP10 Chemically Competent E. coli cells 
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(Invitrogen Ltd, Paisley, UK) and single colonies obtained by plating on LB agar plates containing 
kanamycin (50μg/ml). Vector DNA was isolated and purified by lysis of bacterial cells and 
adsorption of DNA using QIAprep Spin Miniprep kit (Qiagen, Crawley, UK) according to the 
manufacturer’s protocol and eluted in 50μl of elution buffer. The presence of the PCR amplified 
region of interest was confirmed by EcoRI (Fermentas, York, UK) restriction enzyme digestion, 
which cuts the vector either side of the incorporated PCR product. Sequencing of the inserts was 
then carried out using the Sp6 or T7 sequencing primers (Source Bioscience, Nottingham, UK).  
 
Isolation of specific hematopoietic cell types 
CD19+ B-lymphocytes and CD14+ monocytes were isolated using the DynaBeads system 
(Invitrogen, Paisley, UK), according to manufacturer’s protocol. These cell populations were 
isolated from mononuclear cell populations, which were obtained after density gradient 
centrifugation of whole blood samples using Ficoll-Hypaque (BiochromAG, Berlin, Germany). 15 
ml of whole blood was collected in an EDTA tube and re-suspended in 15 ml PBS. The blood-PBS 
mixture was carefully layered on top of 15 ml of Ficoll-Hypaque and centrifuged for 20 minutes at 
800 x g. This resulted is several layers of cell types, including a layer of peripheral blood 
mononuclear cells. This mononuclear cell layer was carefully removed and put into a fresh tube. 
Mononuclear cells were then split into three and used directly for DNA isolation or for isolation of 
CD19+ or CD14+ cells.  
The presence of the DynaBeads still attached to the isolated cells prevented assessment of purity by 
FACS analysis of cell surface markers and so purity of the isolated cell populations was validated 
using RT-PCR for the specific cell surface markers used to isolate the populations. 
The levels of lymphocyte subpopulations in peripheral blood samples taken from Newcastle 85+ 
participants were determined using flow-cytometry (Becton Dickinson FACScan Flow Cytometer) 
for B Cells (CD19+) and T cells (CD3+, CD56-), as described before (16). 
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Statistical analysis 
 Correlations between methylation levels and fractions of specific cell types and correlations 
in methylation levels between the individual genes assessed were investigated by calculating the 
Pearson correlation coefficient. The Pearson correlation coefficient was also used to investigate 
relatedness in methylation at neighboring CpG sites at individual loci, as determined by 
pyrosequencing analysis. The Student t-test was used to assess differences in methylation at specific 
loci or average methylation (of TWIST2, TUSC3, HOXD4, HAND2 and EphA10) between cohorts 
of different ages, with different histories of cancer diagnosis and between sorted cell types. 
Coefficients of variation in the initial 50 samples assessed were calculated by dividing the standard 
deviation by the mean methylation at each individual locus. The Mann-Whitney U test and Fisher’s 
exact test were also used where indicated. 
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Results 
Genes methylated in hematological malignancies show highly variable DNA methylation in 
peripheral blood from 85 year olds. 
DNA methylation levels in peripheral blood samples were assessed using pyrosequencing 
analysis at 15 candidate genes (see Table 2), in an initial subset of 50 participants from the 
Newcastle 85+ Study. Pyrosequencing provides robust quantification of methylation levels so that 
even low levels of inter-individual variation can be quantified. The assays interrogated CpG sites in 
CpG islands surrounding the transcriptional start sites of the respective genes (except for IGF2 
where it targeted the imprinting control region), since these regions would be most likely to 
influence expression of the corresponding gene. The candidate genes were selected to include: 
genes known to be methylated in hematological malignancies (EPHA10, HOXD4, HAND2, MNX1, 
TUSC3, TWIST2, p15 (17-21), and the authors’ unpublished data); genes known to exhibit age or 
malignancy- associated methylation in other tissues (ESR1, RARB2, RASSF1A, MLH1 (22-25)); and 
genes implicated in other age-related diseases (APOE (26)). The imprinted gene IGF2 and HOXA4 
and HOXA5, which exhibit high levels of methylation throughout life (27, 28), were included as 
positive controls. 
Methylation levels (averaged across all CpG sites assayed) were relatively high for several 
candidate genes including EPHA10, HOXD4, HAND2, TUSC3 and TWIST2, which had maximal 
methylation levels of 18 - 35%. However, inter-individual variation in methylation levels was also 
substantial (see Fig. 1A-C for examples). Furthermore, such higher levels of methylation were not 
seen for all genes examined and methylation levels for some genes (such as MLH1, RASSF1A and 
RARB2) exhibited lower or near undetectable levels (Fig. 1 D-F). As shown in Table 2, higher 
levels of CpG island methylation were more common in genes known to be methylated in 
hematological malignancies. In contrast, genes known to exhibit age or malignancy associated 
methylation in other tissues or those implicated in non-malignant disease generally had lower levels 
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of methylation (p=0.009, Mann Whitney U test). Despite these inter-gene differences in absolute 
levels of methylation, inter-individual variation in methylation was similar across all genes (as 
quantified by the respective coefficients of variation (Table 2, p=0.07 for comparison of leukemia-
related versus non-leukemia related genes, Mann Whitney U test)). As expected, high levels of 
methylation were found in the three control genes assessed (HOXA5, HOXA4 and IGF2 (Table 2)). 
The patterns of genes hypermethylated in different types of cancer are known to be cell type 
specific (29) and the results presented here are consistent with the hypothesis that the patterns of 
genes that accumulate methylation during aging are similarly cell type specific and may target 
similar sets of genes to those that are highly methylated in cancers derived from the same cell type.  
 Methylation levels in this initial subset of 50 participants were correlated significantly with 
the percentage of lymphocytes in the WBC population (r2=0.148, p=0.006). Consequently, for all 
studies presented below, methylation levels were corrected for lymphocyte percentage as described 
in the Experimental Procedures section. 
  
Genes which exhibit variable methylation in 85 year olds also exhibit age-related acquisition 
of methylation across the life-course. 
Methylation levels at the five most highly methylated loci, the control loci and a largely 
unmethylated locus (MLH1) were also assessed in DNA from newborns, young adults and fifty-year 
olds. While methylation of the five highly methylated loci was detectable at all ages, this increased 
significantly with increasing age (i.e. newborns < young adults < 50 year olds < 85 year olds), 
confirming that the acquisition of methylation at these loci was age-related (Fig. 2, Supplemental 
Table S1). In contrast, the levels of methylation at the control loci, although consistently high, did 
not show age-related increases across the life-course (Supplemental Fig. S2, Supplemental Table 
S1) and methylation of MLH1 remained low/undetectable methylation in all age groups (Fig. 2G).  
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Age-related methylation exhibits multiple features of malignancy-associated methylation. 
 As described above, there was significant overlap between the genes exhibiting higher 
methylation in DNA from peripheral blood in the subset of 50 participants from the Newcastle 85+ 
Study and those genes known to exhibit cancer-related methylation. To provide a more rigorous 
examination of this apparent concordance between aging and tumorigenesis, we examined DNA 
from an expanded set of samples derived from an additional 327 participants in the Newcastle 85+ 
Study. For this analysis we quantified methylation of the 5 genes which were most highly 
methylated during aging (EPHA10, HOXD4, HAND2, TUSC3, and TWIST2) together with the 
highly methylated, but not age-related, gene HOXA5. This expanded panel of samples confirmed 
the extensive and highly variable methylation at all five loci (Supplemental Fig. S1). One of the 
notable features of methylation in cancer is that methylation across multiple CpG islands is strongly 
correlated (30). To assess if a similar pattern is seen for age–related methylation, methylation levels 
(corrected for lymphocyte percentage) at all five loci were investigated for evidence of co-
methylation. As shown in Table 3, we found highly significant correlations between methylation of 
each of the five genes with methylation levels of any of the other genes. In contrast, no significant 
correlation was found between methylation levels for any of these five loci and that for the highly 
methylated, but not age-related, gene HOXA5.  
 A further feature of cancer cells is the presence of densely methylated alleles, in which most 
or all CpG sites in a promoter associated CpG island are methylated. Such alleles have invariably 
been associated with lack of gene expression (31). To begin to investigate if the identified age-
related methylation can lead to the appearance of densely methylated alleles, similar to those 
observed in cancer cells, we used bisulfite sequencing to investigate methylation at the allelic level 
in one of the participants with higher methylation at two loci (TWIST2 and HOXD4). As shown in 
Fig. 3A, methylation was unequally distributed, with some alleles exhibiting dense methylation at 
all or most CpG sites assessed, while other alleles remained largely methylation free. This 
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demonstrates that age-related methylation can lead to the development of cancer-like densely 
methylated alleles that would likely be transcriptionally inactive. Consequently, clonal expansion of 
the cells that contain these cancer-like methylated alleles would result in cancer-like methylation 
patterns, at least at some loci, without the requirement for further alterations in DNA methylation 
during disease development. 
 
High methylation levels may be detectable prior to the diagnosis of lymphoid malignancy 
 The similarities between the processes of age-associated and cancer-associated DNA 
methylation raises the possibility that altered methylation in apparently healthy cells may precede 
the development of clinically detectable disease and that age-associated methylation may 
predispose individuals to the development of cancer (32). To provide an overall estimate of the 
extent of age-related CpG island methylation in each sample, the methylation values for all 5 age-
related genes were combined (as described in Experimental Procedures) to produce an overall 
methylation level. Interestingly, when the distribution of these combined methylation levels was 
examined, four of the participants (who exhibited the highest methylation levels) were found to lie 
outwith the normal distribution (Fig. 4). Of these, two participants were subsequently diagnosed 
with leukemia or lymphoma compared with none out of 373 participants without unusually high 
methylation levels (p=0.00008, Fisher exact test). As the diagnosis of malignant disease in these 
two patients was up to 2.5 years after the baseline blood sample was taken, this illustrates that 
increased methylation can be detectable for a significant period of time before the clinical diagnosis 
of disease. 
To determine if the patterns of age-associated methylation detected in this population were 
more generally associated with cancer development, methylation levels were compared between 
participants who had had a diagnosis of any type of cancer prior to the study (excluding non-
melanoma skin tumors, n=113) and participants with no history of cancer diagnosis (n=212). 
15 
 
Individuals with a previous diagnosis of cancer had significantly higher methylation levels, 
however the difference between individuals with and without a history of cancer was relatively 
small (10.40% vs. 10.06%, p=0.04). During a three year follow-up period, 72 individuals were 
diagnosed with cancer and methylation levels in this group of individuals were compared with those 
in the 212 cancer-free participants. This confirmed the link between increased methylation and 
cancer diagnosis, as individuals with an incident cancer diagnosis also exhibited significantly higher 
methylation levels at study baseline (10.59% vs. 10.06% respectively, p=0.008). However, as for 
participants with a previous cancer diagnosis, the absolute increase was small. Overall, the results 
suggest that dramatic increases in methylation levels may be detectable prior to cancer diagnosis 
only if examined in the corresponding tissue or cell type (e.g. peripheral blood for prediction of 
hematological malignancies). Small differences in the methylation levels of HOXA5 were also seen 
(mean methylation levels 62.2% for no cancer controls, and 60.4% and 64.19%, for previous cancer 
and incident cancer groups respectively). However, these differences were not statistically 
significant and the direction of change was not consistent in the previous cancer and incident cancer 
groups. 
  
DNA methylation is cell type specific and largely restricted to cells of lymphoid origin. 
 As described above DNA methylation levels correlated with the proportion of lymphocytes 
in the WBC population (r2=0.32, n=377, p-value<1x10-40 for the whole cohort (Supplemental Fig. 
S3)). DNA from individual cell types from participants within the 85+ Study was not available. 
However we obtained whole blood samples from young adults. Multiple different cell populations 
were then purified from these samples and methylation was assessed in DNA extracted from the 
different cell populations. This analysis showed that for the five loci exhibiting age-related 
methylation, DNA from total lymphocytes exhibited higher methylation than total peripheral blood 
leukocytes and that methylation levels in purified myeloid cells (monocytes) were significantly 
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lower (examples in Fig. 3B). Even within the lymphoid compartment, methylation levels differed 
between cell types with B lymphocytes exhibiting significantly higher levels of CpG island 
methylation (Fig. 3B, Supplemental Table S2). While slight differences were seen in the non-age-
related genes HOXA4 and HOXA5, these were far less pronounced (Supplemental Table S2). These 
results are again consistent with a link between age-related and malignancy-related methylation, as 
all five loci are highly methylated specifically in lymphoid and not myeloid malignancies ((20, 33), 
unpublished data). 
 The above analysis is consistent with the correlation which we observed between total 
methylation levels and proportion of lymphocytes in the WBC population in the Newcastle 85 + 
study samples. However, as B lymphocytes exhibit relatively high levels of methylation, it further 
suggests that this correlation may be primarily driven by the fraction of B lymphocytes. Thus we 
examined the correlations between methylation levels and the proportion of B lymphocytes and T 
lymphocytes in the WBC population in the Newcastle 85 + study samples. We observed significant 
correlations for both cell fractions (r2=0.11, p-value<0.0001, for B lymphocytes and r2=0.22, p-
value<0.0001, for T lymphocytes (Supplemental Fig. S3)), but these associations were not as strong 
as for the proportion of lymphocytes as a whole and there was no evidence that the association was 
specifically with B (as opposed to T) lymphocytes. Furthermore, the relative proportion of B 
lymphocytes within the total lymphocyte population did not correlate with methylation levels 
(r2=0.005, p-value=0.12), nor did the relative proportion of T lymphocytes (r2=0.002, p-
value=0.31). The lack of correlation with the relative proportion of B cells is likely due to the 
comparatively low number of B lymphocytes as a proportion of total lymphocytes (average 8.4%). 
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Discussion 
 Both tumor development and aging are associated with similar alterations in the patterns of 
genomic DNA methylation. Both processes result in loss of genome wide methylation alongside 
gains in promoter associated CpG island methylation. This has raised the possibility that 
accumulation of age-related methylation changes may increase the likelihood of malignant 
transformation and thus partly explain the strong link between older age and incidence of most 
cancer types (34). Here we sought to quantify the extent of, and inter-individual variability in, CpG 
island methylation occurring during aging. This analysis demonstrated that even in cancer free 
individuals, methylation levels at promoter associated CpG islands can reach high levels, even at 
presumptive tumor suppressor genes such as TWIST2 and TUSC3. For some genes, we observed 
extensive variation in methylation not only between different age groups but also between 
individuals of the same age, raising the possibility that differential levels of accumulation of age-
related methylation could play an important role in determining susceptibility to the development of 
age-associated disorders, particularly cancer. 
 This analysis found a clear similarity between the patterns of CpG island methylation 
resulting from aging and those previously attributed to the development of cancer. This included the 
altered methylation in a common set of genes, co-ordinate methylation of multiple loci at multiple 
sites throughout the genome and the presence of densely methylated, and likely transcriptionally 
inactive, alleles. This raises two interesting possibilities. One potential explanation for this would be 
that the mechanisms responsible for cancer-related and aging-related alterations in DNA 
methylation may be largely the same. Alternatively, it may be that a significant portion of the 
abnormal methylation found in cancer cells is not acquired during the disease process, but could 
instead be produced by clonal expansion of cells which already contain the abnormal methylation 
patterns. If true, this would suggest that cells with altered methylation states may be at much greater 
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risk for malignant transformation, as suggested by the epigenetic progenitor origin of cancer 
hypothesis (35). 
 Several studies have previously demonstrated an overlap between age-related and cancer-
related methylation. These include studies showing that both processes preferentially involve genes 
regulated by the polycomb group complexes (36), genes which exhibit bivalent chromatin domains 
(37) and genes associated with inter-individual epialleles (38). Our results agreed with this link 
between age-related and cancer-related methylation, as methylation levels were significantly higher 
in genes with a known link to leukemia compared with those chosen due to age/cancer-related 
methylation in other tissues. However, by using highly quantitative methylation analysis our results 
also emphasize that the development of age-related methylation is not inevitable. This is true for 
certain genes, such as MLH1, for which there was no increased methylation across the life-course 
from newborns to 85 years olds. In addition, it was also true for certain individuals even in genes 
displaying clear age-related methylation. The lower range of methylation seen in the 85 year old 
population was equivalent to the average level of methylation in the newborn samples. Indicating 
that some individuals can accumulate very little age-related methylation (at least at the loci assessed 
here) even by 85 years old. This lack of inevitability of age-related methylation suggests that a 
combination of genetic background and environmental/dietary factors may be able to limit or 
prevent any negative impact the accumulation of age-related methylation changes has on health.  
 Co-ordinate methylation across multiple promoter associated CpG islands has been found in 
many types of cancer. For example, it has been suggested that there is a CpG island methylator 
phenotype in colorectal cancer in which a subset of tumors accumulate much more widespread 
methylation of CpG islands (39). Although many other studies have described a CpG island 
methylator phenotypes in other cancers, in the main these have been limited to identifying co-
methylation of genes, i.e. tumors in which high methylation of one gene is associated with increased 
likelihood of higher methylation at the other genes assessed in the study (40). Indeed in a genome 
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wide study of childhood acute lymphoblastic leukemia (ALL), we have found that >1000 loci 
(including all 5 age-related genes investigated in the present study) exhibited coordinated 
methylation levels (i.e. their levels of methylation were significantly correlated, unpublished data). 
Thus the co-ordinate methylation of genes seen in the present study (as detailed in Table 3) appears 
to be analogous to the co-ordinate methylation previously reported in multiple types of cancer. 
Furthermore, as pointed out by Teschendorff and colleagues in a recent review, a key question 
regarding age-related methylation changes is whether they occur predominantly at individual CpG 
sites or are spatially related as in cancer (41). Here we show that not only do neighboring CpG sites 
show strong correlations in methylation levels, but that these correlations extend to multiple loci 
located on separate chromosomes. Thus the potential impact of age-related methylation on 
biological function has to be viewed not just in the context of changes at a single locus, but also co-
ordinate changes in methylation across many loci. 
 The variability in methylation even among healthy individuals which we report here may be 
driven, at least in part, by underlying genetic variation. Twin and population studies have 
demonstrated that epigenetic variation can be associated with genetic variation (42, 43). However, 
these studies have predominantly found SNPs to be associated in cis with methylation at closely 
linked loci  (43). In this study we found that variability at the age-related loci was correlated and the 
loci exhibit co-ordinate patterns of methylation. Thus any genetic variation underlying this 
variability would have to influence methylation levels at multiple loci, unlike the site specific 
correlations observed to date. The possibility of SNPs related to methylation at a genome wide level 
has also been investigated using candidate based approaches targeting genes regulating one carbon 
metabolism or the DNA methyltransferase genes, but no clear impact on DNA methylation levels 
has been identified (44). An alternative explanation is that the variation observed is driven by 
extrinsic factors and a number of environmental exposures and dietary factors have been reported to 
alter epigenetic states (45). 
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The detection of higher levels of methylation in individuals prior to clinical diagnosis of 
leukemia/lymphoma raises the possibility that this could be used for early detection or even 
identification of high risk individuals. This would be consistent with the observation that the two 
cases of leukemia/lymphoma that were subsequently diagnosed in the study population occurred in 
the participants with the highest baseline levels of methylation. It is also notable that while 
methylation of the genes examined increased with age, aberrant promoter methylation of the same 
genes was detectable in PBL samples at all ages (even at birth), suggesting that cells with pre-
existing methylation abnormalities could underlie the development of cancer at all stages 
throughout the life-course. 
In addition, CpG island methylation levels were higher in participants with a cancer 
diagnosis (previous diagnosis or incident cancer). While the increases observed (versus participants 
with no cancer history) were statistically significant, the absolute differences were very small and 
thus assessing methylation levels at the genes in this study would not provide useful information 
regarding overall cancer risk. However, analysis of an expanded set of loci or genome-wide 
methylation studies may identify loci whose methylation status is more predictive of risk of non-
hematological cancers. Indeed, Brennan et al have recently demonstrated that intragenic 
methylation at the ATM locus in peripheral blood samples is associated with risk of breast cancer 
development (46). No statistically significant correlation was found with methylation of the HOXA5 
gene and cancer diagnosis. This may have been due to a lack of power in the study, as small 
differences were observed. However, these changes were not consistent (participants with a 
previous diagnosis had lower methylation levels, whilst those with an incident diagnosis had higher 
levels) and the average methylation levels at HOXA5 across all participants with a cancer diagnosis 
was almost identical to controls. 
A potential explanation for the similarity in genes showing age-related and cancer-related 
methylation could be that non-expressed or functionally unimportant genes may be the predominant 
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targets for both processes. Indeed a number of recent studies have found relatively low correlations 
between aging associated changes in methylation and gene expression (47, 48) and studies in cancer 
have also found that hypermethylation of promoter associated CpG islands is predominantly 
associated with genes that are not expressed in the corresponding normal tissue (49). However, this 
is clearly not always the case. The TWIST2 gene exhibits tumor suppressor like properties in B cell 
leukemia and is expressed in normal differentiated B lymphocytes (20, 50) and yet methylation of 
this gene was not only present in peripheral blood samples, but is predominantly seen in B 
lymphocytes; the same cell type in which it appears to play a role in preventing malignant 
transformation. Subsequent bisulfite sequencing showed that this methylation was characterized by 
the presence of densely methylated alleles. We have observed similar densely methylated alleles in 
ALL and shown that this methylation maintains transcriptional repression of the gene (20). As age-
related methylation, like cancer-related methylation, can affect a large number of loci across the 
genome (36, 37), only a fraction of these epigenetic changes would need to target functionally 
relevant genes to result in significant biological effects. 
Methylation levels varied between the different cell types in sorted peripheral blood samples 
from younger individuals and were largely lymphoid specific. Furthermore, even within in 
lymphoid cells, methylation levels were higher in B lymphocytes. This raises two interesting 
aspects. Firstly, although B cells are one of the less common cell types in the blood, malignancies 
derived from B cells make up over half of hematological cancers. The propensity of B lymphocytes 
for malignant transformation may be explained, in part, by the intrinsically high levels of 
methylation observed in this cell type, further strengthening the link between age-related and 
cancer-related methylation. Secondly, the conceptually simplest explanation for the development of 
age-related methylation is that such changes accumulate in stem cells over time, leading to gradual 
and permanent increases in CpG island methylation in the tissue derived from these stem cells. 
However, the cell type specificity seen here in cells derived from the same pool of stem cells is not 
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fully compatible with this hypothesis and suggests that alternative mechanisms are at least partly 
responsible for age-related methylation. These could involve preferential lymphoid differentiation 
of stem cells with a high CpG island methylation content, differential expansion of short “seeds” of 
methylation in the different cell types (with the “seeds” accumulating in stem cells) or gradual 
deterioration of the fidelity of replicating DNA methylation patterns with increasing age, 
specifically in B lymphocytes. Methylation levels could be further influenced by the lifespan of the 
different cell types, as lymphoid cells are generally more long-lived than myeloid cells. 
Overall these results strengthen the link between cancer-related and age-related methylation 
patterns and show that age-related methylation in specific sets of genes can phenocopy the main 
features of altered methylation patterns seen in cancer cells, implying that the two processes may be 
interlinked. 
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Tables 
Table 1 Primer sequences used for pyrosequencing assays 
            
Gene Forward Primer Reverse Primer Sequencing Primer 
CpG 
Sites 
Distance 
from TSS 
APOE GGAGTTTTATAATTGGATAAGT AAAATCCCAACTCTTTCT (Bio) GGGATTTTTGAGTTTTATT 3 
-24   
+123 
EPHA10 ATTATTTATGGGAATTAATTATTAG CCCACCAATTAAATATTC (Bio) TATTTATGGGAATTAATTATTAGGTA 3 
+28   
+143 
ESR1 GGAGATTAGTATTTAAAGTTGGAGGT CCTAAAAAAAAAACACAACCC (Bio) TGGGATTGTATTTGTTTT 5 
+92   
+294 
HAND2 CCAAATTTTAATTATCTTATA (Bio) GGATTTTTTAGTAAGATTT ATTTTATTACCCAAAACTC 4 
-29   
+185 
HLXB9 TAGTTYGGGTTGTTTAGGAT TACRCTACAACCCTCAAA (Bio) GAAGTYGYGTTGAGTTTTAAG 4 
-161   
+61 
HOXA4 TACACTTCACAAATTAATAACCATAAACTC (Bio) GTTGTTGTAGYGGTAGGTGTTG AACCCAAATTCCCTCCCTT 4 
+31   
+219 
HOXA5 CCACAAATCAAACACACATATC (Bio) GGTTGGTTGTATTTGGGT CTACRACTACAATAACATAAATCT 5 
+30   
+327 
HOXD4 GAAATTAATGGTTATGAGT CCCRAAACTAAAAATCTA (Bio) ATTTGTAGGGYGGTTATTTAGGYGAG 5 
+242   
+398 
IGF2 GGGTTAAGGTAGTTTTTTTGGGAATG AAATATAAAAACCTCCTCCACCTCC (Bio) AGGGGGTTTATTTTTTTAGGAA 3 
DMR 0 
MLH1 AGTTTTTTTTTTAGGAGTGAAGG ATAAAACCCTATACCTAATCTATC (Bio) GTAGTATTYGTGTTTAGTTT 6 
-569   -
375 
TUSC3 GAATAGGATGTTTTGTTAGTT (Bio) TAACTAAACCCTCCCAAATA CCAAATAACAACCACTTTAC 6 
+25   
+116 
p15 GGTTTGGGGTTTYTGTAGTGG CRACCCCTTAACCCAACTAAAAAC (Bio) GAGGAAGTAGTTTAGTTTAAAG 5 
-207   
+41 
RARB2 TATAGAGGAATTTAAAGTGTGGGTTG AAAACTTAAAAACTCCCAACAACCCT (Bio) GTTTTTAAGGTGAGAAATAG 4 
-416   -
118 
RASSF1A GGGGGAGTTTGAGTTTATTGA CTACCCCTTAACTACCCCTTCC (Bio) GGGTYGTATTYGGTTGGAG 5 
+136   
+434 
TWIST2 AACAACTATTTAACAACCCAACCCAAC GGGYGAGTTGGAGTTTTTTTTTATGG (Bio) CAAAACCTTTCCAACAAC 4 
-26   
+208 
 
Table 2 - Variation in CpG island methylation levels 
              
Gene Methylation range (%) Mean (%) SD (%) CoV
1
 
Associated with 
leukemia/lymphoma 
              
HOXD4 7-35 14.8 6 0.399 Yes 
EPHA10 7-31 12 3.9 0.318 Yes 
TUSC3 4-22 8.9 3.4 0.38 Yes 
TWIST2 4-20 8.4 3.3 0.395 Yes 
HAND2 2-18 7.3 2.8 0.382 Yes 
HLXB9 1-15 3.3 2.1 0.371 Yes 
APOE 6-13 8.4 1.9 0.22 No 
p15 2-12 4.9 1.9 0.381 Yes 
ESR1 4-11 5.5 1.6 0.292 No 
RARB2 1-5 2.5 1 0.397 No 
RASSF1A 1-4 2.5 0.7 0.257 No 
MLH1 1-2 1.3 0.3 0.256 No 
Control genes 
HOXA5 28-92 61.5 15.1 
HOXA4 13-64 41.5 11.8 
IGF2 30-50 40.2 4.4 
              
1
CoV; Coefficient of variance 
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Table 3 - Co-methylation of genes in 85+ samples 
            
  TWIST2 TUSC3 HOXD4 HAND2 EPHA10 
TUSC3 
1
r = 0.60 
p<1x10-7      
HOXD4 r = 0.55 p<1x10-7 
r = 0.55 
p<1x10-7    
HAND2 r = 0.29 p<1x10-7 
r = 0.31 
p<1x10-7 
r = 0.38 
p<1x10-7   
EPHA10 r = 0.32 p<1x10-7 
r = 0.33 
p<1x10-7 
r = 0.20 
p<0.0001 
r = 0.32 
p<1x10-7  
HOXA5 r = 0.04     p = 0.62 
r = -0.03    
p = 0.72 
r = -0.002   
p = 0.98 
r = -0.02    
p = 0.77 
r = 0.003    
p = 0.97 
            
1
Pearson correlation coefficient 
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Figure Legends 
 
Figure 1. Examples of variation in methylation in peripheral blood samples. 
Examples of genes with high levels (A-C) or low levels (D-F) of age-related methylation in 
Newcastle 85+ study samples. Methylation levels were assessed by pyrosequencing in 
each of the indicated genes in an initial sample set from 50 85+ study participants. Y-axis 
scale is the same for all genes (0-25%), except for HOXD4 (0-40%), as this gene exhibited 
the highest levels of methylation. Error bars indicate standard error of the mean. 
 
Figure 2. Methylation levels of 5 most variable genes are age-related. Methylation 
levels at the indicated genes were assessed by pyrosequencing in individuals from 3 
younger age groups (50 participants in each, median ages 0, 27 and 50 years), in addition 
to the Newcastle 85+ participants. The combination of the 5 most variable genes (A), as 
well as each of the 5 genes individually (B-F) exhibit increasing levels of methylation with 
increasing age. In contrast the MLH1 gene (G) exhibits no significant differences between 
the age groups. 
 
Figure 3. DNA methylation is non-randomly distributed in peripheral blood. A) 
Bisulfite sequencing at the TWIST2 and HOXD4 loci. To assess methylation at the allelic 
level, bisulfite sequencing was performed at two loci (TWIST2 and HOXD4, as indicated) 
in a sample with high levels of methylation at both loci. The CpG sites within each allele 
are represented by the horizontal rows of circles. A filled in circle indicates methylated and 
an open circle the absence of methylation. For TWIST2, 23 consecutive CpG sites, 
between +38 and +181 relative to the transcriptional start site, were sequenced. For 
HOXD4, 13 consecutive CpG sites, between +262 and +377 relative to the transcriptional 
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start site, were sequenced. B) DNA methylation is highly variable between cell types. 
Specific cell subsets were isolated from 10 peripheral blood samples. These included total 
peripheral blood leukocytes (PBL), mononuclear cells (MNC), B lymphocytes (B-cells), 
monocytes and total lymphocytes. All five genes exhibited very similar distributions across 
the cell types as illustrated by TWIST2 and TUSC3. Methylation levels for all genes 
assessed are shown in Supplemental Table S2. 
 
Figure 4. Q-Q plot to assess the normality of distribution of methylation data. 
Methylation for all samples, averaged across the five genes and normalized for percentage 
of lymphocytes, was found to exhibit a largely normal distribution. Four samples with the 
highest methylation were found to lie above the line of normal distribution. As indicated two 
of those individuals were subsequently diagnosed with leukemia/lymphoma. 
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Supplemental Figure S1. Methylation levels of 5 age-related and one control gene in expanded sample set. 
Pyrosequencing analysis of 5 age-related genes and HOXA5 in expanded sample set, confirming high levels of 
methylation and extensive variation across the Newcastle 85+ sample set. 
 
 
 
 
 
Supplemental Fig. 1
Supplemental Table 1 - Methylation changes significantly between individuals of different ages
Gene name TWIST2 TUSC3 HOXD4 EPHA10 HAND2
5 genes 
combined 1 MLH1
Newborn vs. young adult (27Y)2
0.886
3
1.19X10
-10
5.21X10
-17
0.003 5.14X10
-18
1.02X10
-19
0.704
young adult (27Y) vs. older adult (50Y)
5.07X10
-07
1.16X10
-14
7.08X10
-08
1.66X10
-06
5.75X10
-10
1.05X10
-16
0.214
Older adult (50Y) vs.elderly (85Y)
2.93X10
-07
0.008 1.04X10
-04
3.97X10
-08
0.641 1.42X10
-06
0.002
Control Gene name HOXA5 HOXA4 IGF2
Newborn vs. young adult (27Y)
0.021 1.68X10
-07
3.75X10
-05
young adult (27Y) vs. older adult (50Y)
0.861 0.246 0.678
Older adult (50Y) vs.elderly (85Y)
0.059 0.344 0.060
1Average methylation for all samples across the 5 genes (TWIST2, TUSC3, HOXD4, EPHA10, HAND2 ).
2Groups compared. Median ages 0 years (newborn), 27 years (young adult), 50 years (older adult) and 85 years (elderly).
3
p-value, as determined by one way ANOVA, for comparison of methylation between indicated groups. Values 
highlighted in red indicate signifcant increases with age, highlighted in blue indicate significant decreases.
  
Supplemental Figure S2. Methylation levels in control genes in different age groups. Pyrosequencing analysis of the three 
control genes (HOXA5, HOXA4, IGF2), as indicated, in groups of individuals with median ages 0, 27, 50 and 85 years old (n=50 
for each group). For all three genes methylation levels remain high at all age groups tested and methylation levels do not show clear 
evidence of increasing across the life-course (with the exception of an increase in HOXA4 methylation early in life). 
 
Supplemental Figure S3. Correlation between methylation levels and lymphocyte cell populations. Scatter plot indicating the 
correlations between averaged methylation levels and the percentage of total lymphocytes (upper panel), T-lymphocytes (middle 
panel) and B-lymphocytes (lower panel) (as a fraction of total WBC count). R2 values (coefficient of determination) for each of the 
correlations and the corresponding p-values are indicated on the respective plots. 
 
Supplemental Table 2 - Variation in CpG island methylation by cell type     
              
  Mean
1
 (%) TWIST2 TUSC3 HOXD4 EPHA10 HAND2 HOXA5 HOXA4 
PBL 8.05 5.24 6.62 10.70 9.23 8.46 53.54 38.5 
MNC 9.07 5.61 8.48 13.01 9.80 8.45 52.62 39.62 
B cells 15.402 12.94 15.99 21.83 15.79 10.47 57.35 42.88 
Monocytes 5.803 3.13 4.94 7.42 7.48 6.02 52.44 37.05 
lymphocytes 9.364 6.57 8.21 12.62 10.91 8.50 56.51 40.95 
                  
1Mean average of the 5 genes which exhibit age-related methylation 
2Significantly increased vs. PBL (p<0.001) and vs. lymphocytes (p<0.001) 
3Significantly decreased vs. PBL (p <0.001) 
  
4Significantly increased vs. PBL (p <0.05)      
 
